Thromboreductin 0,5 mg Capsules

Indication

Treatment of essential thrombocythaemia to reduce platelet count.

Dosage (summary)

Start with 0.5 mg daily, increase weekly by 0.5 mg; usual maintenance 1.5-3 mg daily.

Onset of Action / Duration

Onset: 2 weeks, Duration: up to 5 mg daily.

Special Populations

• Elderly
• Renal impairment
• Hepatic impairment

Pregnancy & Breastfeeding

Contraindicated in pregnancy; unknown if excreted in breast milk.

Key Drug Interactions

• Aspirin (increased bleeding risk)
• CYP1A2 inhibitors
• QTc prolonging agents

Contraindications

• Hypersensitivity to anagrelide
• Severe renal insufficiency
• Moderate to severe hepatic insufficiency
• Cardiovascular disease grade 3 or 4

Common side effects

• Headaches
• Palpitations
• Oedema
• Nausea
• Diarrhoea

Counselling Points

• Monitor platelet counts regularly
• Avoid abrupt treatment discontinuation
• Report signs of thrombotic events